Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(943)
•••
Post by Nailbiter2on Jun 24, 2023 9:33am
251 Views
Post# 35512701

SZLS Warrant Repricing

SZLS Warrant Repricing
Image preview

StageZero Life Sciences, Ltd. this morning announced a temporary repricing of warrants that are expiring in 2023 and 2024 for the period of July 5 - 10, 2023; new exercise price CDN$0.065. The press release can be seen here.
THE COMPANY BELIEVES THAT THIS TEMPORARY REPRICING PRESENTS A BUYING OPPORTUNITY TO WARRANT HOLDERS WHO HAVE PARTICIPATED IN PREVIOUS FINANCINGS. THE FUNDS FROM THIS REPRICING WILL BE USED FOR GROWTH FOCUSED ACTIVITIES SUCH AS THE METRICS II STUDY AND SUPPORT OF THE GROWING LIST OF CORPORATE PARTNERSHIPS. THE COMPANY’S FOCUS IS ON EMPLOYERS, CLINIC SYSTEMS AND LABS AND ANNOUNCEMENTS ON THESE WILL CONTINUE TO BE MADE OVER THE COMING WEEKS AND MONTHS.
If you wish to exercise your warrants please reach out to Sherry Cui at scui@stagezerols.com. If you have any questions please reach out to investor relations at rgreco@stagezerols.com
Thank you for your continued support.
Rebecca Greco
Head of Investor Relations
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities